Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
Michela Piezzo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Germira Di Gioia(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Vincenzo Di Lauro(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giuseppina Fusco(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Daniela Cianniello(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Stefania Cocco(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Matilde Pensabene(University of Naples Federico II), Claudia Martinelli(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Roberta Caputo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Francesco Nuzzo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")
Cited by 194
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282